Cargando…
Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer
Repeated cycles of first-line chemotherapy drugs such as doxorubicin (DOX) and cisplatin (CIS) trigger frequent chemoresistance in recurrent urothelial bladder cancer (UBC). Nitroxoline (NTX), an antibiotic to treat urinary tract infections, has been recently repurposed for cancer treatment. Here we...
Autores principales: | Lin, Wenfeng, Sun, Jingkai, Sadahira, Takuya, Xu, Naijin, Wada, Koichiro, Liu, Chunxiao, Araki, Motoo, Xu, Abai, Watanabe, Masami, Nasu, Yasutomo, Huang, Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375225/ https://www.ncbi.nlm.nih.gov/pubmed/34421363 http://dx.doi.org/10.7150/ijbs.63125 |
Ejemplares similares
-
Nitroxoline inhibits bladder cancer progression by reversing EMT process and enhancing anti-tumor immunity
por: Xu, Naijin, et al.
Publicado: (2020) -
The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer
por: Xu, Naijin, et al.
Publicado: (2019) -
Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma
por: Li, Xiezhao, et al.
Publicado: (2017) -
Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment
por: Lin, Wenfeng, et al.
Publicado: (2021) -
A second opinion pathology review improves the diagnostic concordance between prostate cancer biopsy and radical prostatectomy specimens
por: Maehara, Takanori, et al.
Publicado: (2021)